RE:RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024Biologics is a new technology area, and as such will continue to gain traction against traditional small molecule chemistry. Biologic drugs, like ONCY's pelareorep, will now enjoy a longer exemption period of 13 years of market exclsusivty under the Inflation Reduction Act, compared to nine years for small molecule drugs. And now that the first wave of biologic patent expirations is upon Big Pharma and many large pharmaceutical companies will see revenue decline as patents expire on major commercial biologics. Consequently, biopharmas will look to rebuild their pipeline through M&A and licensing deals.
As such, innovative small late-stage biotech companies are increasingly aware that potential suitors are set to aggressively seek opportunities to acquire or partner with them, and M&A consultants are advising that these biotech companies should position themselves for such an expeditious exit if that is their desired outcome.